ObsEva (NASDAQ: OBSV) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare ObsEva to related businesses based on the strength of its analyst recommendations, institutional ownership, risk, earnings, dividends, profitability and valuation.
This is a summary of recent ratings and target prices for ObsEva and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ObsEva presently has a consensus price target of $20.33, suggesting a potential upside of 109.62%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.56%. Given ObsEva’s stronger consensus rating and higher probable upside, research analysts plainly believe ObsEva is more favorable than its competitors.
This table compares ObsEva and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
35.9% of ObsEva shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares ObsEva and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|ObsEva Competitors||$290.27 million||$35.99 million||60.31|
ObsEva’s competitors have higher revenue and earnings than ObsEva.
ObsEva competitors beat ObsEva on 6 of the 11 factors compared.
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea. OBE001 (nolasiban) is an oral, new generation oxytocin antagonist with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART). BE022 is an orally active small molecule dinoprost (PGF2a) receptor antagonist.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.